Related references
Note: Only part of the references are listed.PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
Jianfeng Shen et al.
CANCER RESEARCH (2019)
Going to extremes: determinants of extraordinary response and survival in patients with cancer
Flurina A. M. Saner et al.
NATURE REVIEWS CANCER (2019)
Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2018)
Who are the long-term survivors of high grade serous ovarian cancer?
Claire Hoppenot et al.
GYNECOLOGIC ONCOLOGY (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott et al.
NATURE MEDICINE (2018)
Comparative molecular characterization of typical and exceptional responders in glioblastoma
Kristin Wipfler et al.
Oncotarget (2018)
A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature
Go Nishikawa et al.
EUROPEAN JOURNAL OF CANCER (2018)
First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial
Mothaffar Rimawi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Diagnosis and Treatment of Ovarian Cancer
Brian Orr et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
Liya Ding et al.
CELL REPORTS (2018)
Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics
Sarah S. Kalia et al.
GENETICS IN MEDICINE (2017)
NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma
Mark R. Gilbert et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA
C. Lance Cowey et al.
FUTURE ONCOLOGY (2017)
Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma
Peter G. Rose et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2017)
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer
Ramaswamy Govindan et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos et al.
LANCET (2017)
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial
Robert L. Coleman et al.
LANCET ONCOLOGY (2017)
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Padmanee Sharma et al.
LANCET ONCOLOGY (2017)
Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients
Francesco Sclafani et al.
ONCOLOGIST (2017)
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study
Matteo Lambertini et al.
CLINICAL BREAST CANCER (2017)
A retrospective study of docetaxel and bevacizumab as a second- or later-line chemotherapy for non-small cell lung cancer
Koichi Kurishima et al.
MOLECULAR AND CLINICAL ONCOLOGY (2017)
A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin
Neeraj Agarwal et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer
Guy A. van Hazel et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)
Maura N. Dickler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Long-term Outcome of an Organ Preservation Program After Neoadjuvant Treatment for Rectal Cancer
Milou H. Martens et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas
M. C. Pietanza et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Toward a Shared Vision for Cancer Genomic Data
Robert L. Grossman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Treatment of lung large cell neuroendocrine carcinoma
Giuseppe Lo Russo et al.
TUMOR BIOLOGY (2016)
Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences
Sebastian Moran et al.
EPIGENOMICS (2016)
Long-term Outcome of an Organ Preservation Program After Neoadjuvant Treatment for Rectal Cancer
Milou H. Martens et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression
Etienne Becht et al.
GENOME BIOLOGY (2016)
Innate Immune Recognition of Cancer
Seng-Ryong Woo et al.
ANNUAL REVIEW OF IMMUNOLOGY VOL 33 (2015)
Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)
Ramesh K. Ramanathan et al.
CANCER (2015)
Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline
H. Hirte et al.
CURRENT ONCOLOGY (2015)
Outcome of Recurrent Uterine Papillary Serous Carcinoma Treated With Platinum-Based Chemotherapy
Haider Mahdi et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2015)
PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed plus Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel plus Carboplatin plus Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non-Small-Cell Lung Cancer
Ralph G. Zinner et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman et al.
NATURE METHODS (2015)
BIOMARKERS Exceptional responders-discovering predictive biomarkers
Naoko Takebe et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma
Elizabeth R. Gerstner et al.
NEURO-ONCOLOGY (2015)
Cooperative Group Trials in the Community Setting
James Lloyd Wade et al.
SEMINARS IN ONCOLOGY (2015)
A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral gamma-Secretase Inhibitor PF-03084014
Wells A. Messersmith et al.
CLINICAL CANCER RESEARCH (2015)
Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer
G. K. Prithviraj et al.
DISEASES OF THE ESOPHAGUS (2015)
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
F. Barlesi et al.
ANNALS OF ONCOLOGY (2014)
A Randomized Phase 2 Trial of Gemcitabine/Cisplatin With or Without Cetuximab in Patients With Advanced Urothelial Carcinoma
Maha Hussain et al.
CANCER (2014)
First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: Pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials
R. J. Young et al.
EUROPEAN JOURNAL OF CANCER (2014)
Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A. McArthur et al.
LANCET ONCOLOGY (2014)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al.
LANCET ONCOLOGY (2014)
Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
Nikhil Wagle et al.
CANCER DISCOVERY (2014)
Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy
S. Lorenzen et al.
ANNALS OF ONCOLOGY (2013)
Phase II study of everolimus in metastatic urothelial cancer
Matthew I. Milowsky et al.
BJU INTERNATIONAL (2013)
Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic Downstaging and Long-term Outcomes: Results from a Retrospective Study at the MD Anderson Cancer Center
Siobhan P. Lynch et al.
EUROPEAN UROLOGY (2013)
PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer
Jyoti D. Patel et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information Repository
Kenneth Clark et al.
JOURNAL OF DIGITAL IMAGING (2013)
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
Sandra M. Swain et al.
LANCET ONCOLOGY (2013)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study
John F. R. Robertson et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
J. Souglakos et al.
BRITISH JOURNAL OF CANCER (2012)
A clinical review of treatment outcomes in glioblastoma multiforme-the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival?
K. Rock et al.
BRITISH JOURNAL OF RADIOLOGY (2012)
Oral vinorelbine in metastatic breast cancer: A review of current clinical trial results
Matti Aapro et al.
CANCER TREATMENT REVIEWS (2012)
Cancer of unknown primary site
Nicholas Pavlidis et al.
LANCET (2012)
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
Luis Paz-Ares et al.
LANCET ONCOLOGY (2012)
Absolute quantification of somatic DNA alterations in human cancer
Scott L. Carter et al.
NATURE BIOTECHNOLOGY (2012)
A Randomized, Phase II Trial of Standard Triweekly Compared with Dose-Dense Biweekly Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer: XELOX-A-DVS (Dense Versus Standard)
Herbert Hurwitz et al.
ONCOLOGIST (2012)
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Gopa Iyer et al.
SCIENCE (2012)
Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: A phase II study of the Gynecologic Oncology Group
Bradley J. Monk et al.
GYNECOLOGIC ONCOLOGY (2011)
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer
Michel Ducreux et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Docetaxel in the management of head and neck cancer
Francesco Caponigro et al.
ANTI-CANCER DRUGS (2009)
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
Astrid Lievre et al.
BMC CANCER (2009)
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study
J. W. Valle et al.
BRITISH JOURNAL OF CANCER (2009)
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
C. Yoo et al.
BRITISH JOURNAL OF CANCER (2009)
Phase 2 Trial of Carboplatin, Weekly Paclitaxel, and Biweekly Bevacizumab in Patients With Unresectable Stage IV Melanoma A North Central Cancer Treatment Group Study, N047A
Domingo G. Perez et al.
CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group study
Carol Aghajanian et al.
GYNECOLOGIC ONCOLOGY (2009)
Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124
Primo N. Lara et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications
Mahul B. Amin
MODERN PATHOLOGY (2009)
Experience with irinotecan for the treatment of malignant glioma
James J. Vredenburgh et al.
NEURO-ONCOLOGY (2009)
Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer
Mari Nakabayashi et al.
BJU INTERNATIONAL (2008)
Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine lelomyosarcoma: A Gynecologic Oncology Group phase II trial
Martee L. Hensley et al.
GYNECOLOGIC ONCOLOGY (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin:: A study of the arbeitsgemeinschaft internistische onkologie
Salah-Eddin Al-Batran et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type
P. Pautier et al.
ANNALS OF ONCOLOGY (2007)
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
Robert A. Burger et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers
J. Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer:: The Gruppo Oncologico Nord Ovest
Alfredo Falcone et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial
Ulrich Gatzemeier et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
Bruce J. Giantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
Vicki L. Goodman et al.
CLINICAL CANCER RESEARCH (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Review of capecitabine as oral treatment of gastric, gastroesophageal, and Esophageal cancers
Jaffer Ajani
CANCER (2006)
Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF
K Sumpter et al.
BRITISH JOURNAL OF CANCER (2005)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study
E Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: A phase II study
PJ Hoskins et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
First-line Herceptin (R) monotherapy in metastatic breast cancer
CL Vogel et al.
ONCOLOGY (2001)
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
A de Gramont et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
